Rallybio Corporation
NASDAQ:RLYB · NASDAQ Capital Market
+$0.01 today
Vol 0.02M · Avg 0.25M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $41.3M |
| Short-term Investments | $5.5M |
| Other Current | $6.7M |
| Total Current Assets | $53.5M |
| PP&E (Net) | $172.0K |
| Other Non-current | $810.0K |
| Total Non-current Assets | $982.0K |
| Total Assets | $54.5M |
Analysis
Selected assets total $54.5M for Latest. The largest visible component is Cash & Equivalents at $41.3M, about 75.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.4M +125.7% | $13.9M -43.2% | $24.5M -57.0% | $57.0M -67.5% | $175.3M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $23.4M -54.7% | $51.6M -39.6% | $85.4M -23.7% | $112.0M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $2.5M +153.0% | $995.0K -51.6% | $2.1M +95.6% | $1.1M +165.8% | $395.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $61.3M -9.7% | $67.8M -40.9% | $114.8M -36.0% | $179.5M -0.8% | $180.9M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $198.0K -25.8% | $267.0K -54.9% | $592.0K -34.9% | $909.0K +77.9% | $511.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 -100.0% | $239.0K +696.7% | $30.0K -96.3% | $805.0K | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $810.0K | $0 | $0 | $0 | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.0M +277.5% | $267.0K -67.9% | $831.0K -11.5% | $939.0K -28.6% | $1.3M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $62.3M -8.6% | $68.1M -41.1% | $115.6M -35.9% | $180.4M -1.0% | $182.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $126.0K -54.7% | $278.0K -71.5% | $976.0K -12.4% | $1.1M +84.7% | $603.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $212.0K -75.0% | $848.0K | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.5M -52.9% | $3.1M -2.2% | $3.2M -32.7% | $4.7M +57.1% | $3.0M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $4.2M -32.3% | $6.2M -32.6% | $9.3M -13.8% | $10.7M +64.0% | $6.6M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 -100.0% | $374.0K | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 -100.0% | $212.0K | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 +100.0% | -$374.0K -1268.7% | $32.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $82.0K -61.3% | $212.0K +22.5% | $173.0K -53.7% | $374.0K +1068.8% | $32.0K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $4.3M -33.3% | $6.5M -31.6% | $9.4M -15.1% | $11.1M +68.9% | $6.6M | $14.7B | $3.7B | $9.6B |
| Common Stock | $4.0K +0.0% | $4.0K +0.0% | $4.0K +0.0% | $4.0K +33.3% | $3.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$302.0M -3.1% | -$293.0M -24.6% | -$235.2M -46.4% | -$160.7M -70.9% | -$94.0M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $18.0K -73.5% | $68.0K +353.3% | $15.0K +107.0% | -$214.0K -501963708467436.5% | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $58.0M -6.0% | $61.7M -41.9% | $106.2M -37.3% | $169.3M -3.6% | $175.6M | $9.1B | $7.7B | $3.3B |
| Total Debt | $176.0K +14.3% | $154.0K -60.7% | $392.0K -29.4% | $555.0K | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$31.2M -126.9% | -$13.7M +43.0% | -$24.1M +57.3% | -$56.4M +67.8% | -$175.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$156.64M
Boundless Bio, Inc.
BOLD
$31.90M
iBio, Inc.
IBIO
$25.97M
Klotho Neurosciences, Inc.
KLTO
$20.08M
Exicure, Inc.
XCUR
$15.81M
TAO Synergies Inc.
TAOX
$12.09M
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$9.39M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
Intensity Therapeutics, Inc.
INTS
$7.17M
Iterum Therapeutics plc
ITRM
$1.60M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does RLYB have?
Rallybio Corporation (RLYB) reported $31.37M in cash and equivalents in fiscal 2025.
How much debt does RLYB carry?
Rallybio Corporation (RLYB) reported $176,000.00 of total debt, with net debt of -$31,198,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.